troglitazone has been researched along with Disease Models, Animal in 50 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 7.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 7.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "Troglitazone is a newly developed antidiabetic drug that has been shown to improve insulin resistance and hyperinsulinemia both in diabetic animal models and in patients with non-insulin-dependent diabetes mellitus." | 7.69 | Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. ( Arakawa, K; Saku, K; Zhang, B, 1997) |
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 5.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARalpha null mice at any of the time points examined." | 5.31 | Pretreatment with troglitazone decreases lethality during endotoxemia in mice. ( Gimble, J; Gipson, J; Gonzalez, F; Hill, M; Hoffhines, A; Johnson, J; Novosad, B; Peters, J; Reynolds, K, 2002) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 5.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 3.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "Recently, we found that profound anorexia observed in a catabolic model induced by chronic glucocorticoid (dexamethasone, Dex) injection could be associated with strong hyperleptinemia." | 3.73 | Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. ( Caldefie-Chézet, F; Enreille-Leger, A; Poulin, A; Vasson, MP, 2005) |
| " In this study, we investigated the effect of a TZD, troglitazone, on inflammation and fibrogenesis in the pancreas of an experimental model of chronic pancreatitis." | 3.73 | Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation. ( Hisada, S; Kobayashi, M; Shimizu, K; Shiratori, K, 2005) |
| " We previously demonstrated that chronic pretreatment with a thiazolidinedione peroxisome proliferator-activated receptor (PPAR)-gamma activator, troglitazone, improves recovery of left ventricular (LV) function and substrate metabolism after ischemia and reperfusion, without causing arrhythmias." | 3.72 | Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. ( Gen, M; Greyson, C; Kinugawa, K; Lee, J; Long, CS; Lu, L; Schwartz, GG; Xu, Y, 2003) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 3.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "2% troglitazone was administered from 1 month to 7 months of age in WBN/Kob rats with spontaneous chronic pancreatitis." | 3.71 | Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. ( Fujiwara, T; Hayashi, N; Horikoshi, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2002) |
| " In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice." | 3.71 | Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002) |
| "Troglitazone (TRG) is an orally active antidiabetic agent that increases insulin sensitivity in models of non-insulin-dependent diabetes mellitus (NIDDM), subsequently reducing hyperinsulinemia and hyperglycemia." | 3.69 | Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. ( Cornicelli, JA; Davis, JA; O'Rourke, CM; Saltiel, AR, 1997) |
| "Troglitazone is a newly developed antidiabetic drug that has been shown to improve insulin resistance and hyperinsulinemia both in diabetic animal models and in patients with non-insulin-dependent diabetes mellitus." | 3.69 | Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. ( Arakawa, K; Saku, K; Zhang, B, 1997) |
| "Troglitazone was found to increase mitochondrial permeability transition (MPT) in the liver mitochondria of diabetic rats to a greater extent than in control rats, whereas mitochondrial membrane potential and oxidative phosphorylation were not affected." | 1.48 | Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat. ( Ito, K; Sato, T; Segawa, M; Sekine, S, 2018) |
| "MIA Paca2 and PANC-1 human pancreatic cancer cell lines were used." | 1.46 | In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. ( Fujita, M; Hasegawa, A; Okamura, N; Yamamori, M, 2017) |
| "Troglitazone (TGZ) was used as an insulin sensitizer." | 1.39 | Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats. ( Asai, F; Kaji, N; Nagakubo, D; Ohno-Ichiki, K; Okuno, A; Shirai, M; Takahashi, A, 2013) |
| " Following dosing with troglitazone, there was a loss of the large lipid droplets in the human hepatocytes, a decrease in the amount of lipid as observed in frozen sections of liver stained by Oil-red-O, and a decrease in the expression of two bile acid transporters, BSEP and MRP2." | 1.38 | Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. ( Foster, JR; Jacobsen, M; Kenna, G; Morikawa, Y; Salmu, J; Schulz-Utermoehl, T; Wilson, ID, 2012) |
| "Sepsis is associated with impaired PMN function, including chemotaxis." | 1.35 | Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. ( Keshamouni, VG; Milam, JE; Narala, VR; Newstead, MW; Reddy, RC; Standiford, TJ, 2008) |
| "Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling." | 1.35 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. ( Gangireddy, SR; Hogaboam, CM; Hu, B; Keshamouni, VG; Milam, JE; Phan, SH; Reddy, RC; Standiford, TJ; Thannickal, VJ, 2008) |
| "Troglitazone treatment improved ischemic tolerance by improving glucose metabolism in the myocardium of those rats." | 1.34 | Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats. ( Anzawa, R; Horikoshi, K; Mochizuki, S; Seki, S; Taniguchi, M, 2007) |
| "Renal ischemia-reperfusion injury affects the long-term outcome of renal graft survival." | 1.34 | Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. ( Arakawa, T; Doi, S; Kawai, T; Kohno, N; Masaki, T; Naito, T; Nakashima, A; Takahashi, S; Yorioka, N, 2007) |
| "Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations." | 1.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone treatment significantly improved the left ventricular diastolic dynamics of DM rats: deceleration time (msec) of early diastolic inflow decreased significantly (treated 52 +/- 3 vs untreated 64 +/- 5, p = 0." | 1.31 | Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment. ( Matsuo, H; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Yao, L, 2001) |
| "Troglitazone treatment restored those alterations in PTPase activity in the particulate fraction and the amounts of LAR, PTP1B and SH-PTP2 in both fractions of visceral and epididymal adipose tissues of OLETF rats." | 1.31 | Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. ( Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H, 2002) |
| "Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARalpha null mice at any of the time points examined." | 1.31 | Pretreatment with troglitazone decreases lethality during endotoxemia in mice. ( Gimble, J; Gipson, J; Gonzalez, F; Hill, M; Hoffhines, A; Johnson, J; Novosad, B; Peters, J; Reynolds, K, 2002) |
| " These data demonstrate that chronic administration of troglitazone is associated with a greatly attenuated responsiveness towards inducers of hepatic TNF-alpha and IL-6 production." | 1.31 | Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. ( Bedoucha, M; Boelsterli, UA; Sigrist, S, 2000) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 1.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| "Rosiglitazone treatment increased the triglyceride content of the steatotic livers of A-ZIP/F-1 and ob/ob mice, but not the "lean" livers of fat-transplanted A-ZIP/F-1 mice." | 1.31 | Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. ( Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C, 2000) |
| " We studied the effects of TRZ on the hepatotoxicity of carbon tetrachloride (CCl(4)) and acetaminophen (APAP) in rats, both of which exert their toxic effects through bioactivation associated with cytochrome P450 3A (CYP3A) and 2E1 (CYP2E1)." | 1.31 | Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. ( Kaneko, T; Li, J; Qin, LQ; Sato, A; Wang, PY; Wang, Y, 2002) |
| "The incidence and severity of xanthomata in the digital joints were also decreased significantly in the three treated groups." | 1.30 | Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. ( Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (10.00) | 18.2507 |
| 2000's | 33 (66.00) | 29.6817 |
| 2010's | 10 (20.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantello, BC | 1 |
| Cawthorne, MA | 1 |
| Cottam, GP | 1 |
| Duff, PT | 1 |
| Haigh, D | 1 |
| Hindley, RM | 1 |
| Lister, CA | 1 |
| Smith, SA | 1 |
| Thurlby, PL | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Lane, SL | 1 |
| Doyle, AS | 1 |
| Bales, ES | 1 |
| Houck, JA | 1 |
| Lorca, RA | 1 |
| Moore, LG | 1 |
| Julian, CG | 1 |
| Fujita, M | 1 |
| Hasegawa, A | 1 |
| Yamamori, M | 1 |
| Okamura, N | 1 |
| Mak, A | 1 |
| Kato, R | 1 |
| Weston, K | 1 |
| Hayes, A | 1 |
| Uetrecht, J | 1 |
| Segawa, M | 1 |
| Sekine, S | 1 |
| Sato, T | 1 |
| Ito, K | 1 |
| Jia, R | 1 |
| Oda, S | 1 |
| Tsuneyama, K | 1 |
| Urano, Y | 1 |
| Yokoi, T | 1 |
| Okuno, A | 1 |
| Kaji, N | 1 |
| Takahashi, A | 1 |
| Nagakubo, D | 1 |
| Ohno-Ichiki, K | 1 |
| Shirai, M | 1 |
| Asai, F | 1 |
| Aktas, BH | 1 |
| Qiao, Y | 1 |
| Ozdelen, E | 1 |
| Schubert, R | 1 |
| Sevinc, S | 1 |
| Harbinski, F | 1 |
| Grubissich, L | 1 |
| Singer, S | 1 |
| Halperin, JA | 1 |
| Sasagawa, S | 1 |
| Nishimura, Y | 1 |
| Koiwa, J | 1 |
| Nomoto, T | 1 |
| Shintou, T | 1 |
| Murakami, S | 1 |
| Yuge, M | 1 |
| Kawaguchi, K | 1 |
| Kawase, R | 1 |
| Miyazaki, T | 1 |
| Tanaka, T | 2 |
| Reddy, RC | 2 |
| Narala, VR | 1 |
| Keshamouni, VG | 2 |
| Milam, JE | 2 |
| Newstead, MW | 1 |
| Standiford, TJ | 2 |
| Jin, M | 1 |
| Saekusa, Y | 1 |
| Dewa, Y | 1 |
| Nishimura, J | 1 |
| Matsumoto, S | 1 |
| Shibutani, M | 1 |
| Hasumi, K | 1 |
| Mitsumori, K | 1 |
| Foster, JR | 1 |
| Jacobsen, M | 1 |
| Kenna, G | 1 |
| Schulz-Utermoehl, T | 1 |
| Morikawa, Y | 1 |
| Salmu, J | 1 |
| Wilson, ID | 1 |
| Wagnerberger, S | 1 |
| Spruss, A | 1 |
| Kanuri, G | 1 |
| Stahl, C | 1 |
| Schröder, M | 1 |
| Vetter, W | 1 |
| Bischoff, SC | 1 |
| Bergheim, I | 1 |
| Celinski, K | 1 |
| Dworzanski, T | 1 |
| Fornal, R | 1 |
| Korolczuk, A | 1 |
| Madro, A | 1 |
| Slomka, M | 1 |
| Reynolds, K | 1 |
| Novosad, B | 1 |
| Hoffhines, A | 1 |
| Gipson, J | 1 |
| Johnson, J | 1 |
| Peters, J | 1 |
| Gonzalez, F | 1 |
| Gimble, J | 1 |
| Hill, M | 1 |
| Tagami, S | 1 |
| Honda, T | 1 |
| Yoshimura, H | 1 |
| Homma, H | 1 |
| Ohno, K | 1 |
| Ide, H | 1 |
| Sakaue, S | 1 |
| Kawakami, Y | 1 |
| Saubermann, LJ | 1 |
| Nakajima, A | 2 |
| Wada, K | 2 |
| Zhao, S | 1 |
| Terauchi, Y | 1 |
| Kadowaki, T | 3 |
| Aburatani, H | 1 |
| Matsuhashi, N | 1 |
| Nagai, R | 1 |
| Blumberg, RS | 2 |
| Xu, Y | 1 |
| Lu, L | 1 |
| Greyson, C | 1 |
| Lee, J | 1 |
| Gen, M | 1 |
| Kinugawa, K | 1 |
| Long, CS | 1 |
| Schwartz, GG | 1 |
| van Westerloo, DJ | 1 |
| Florquin, S | 1 |
| de Boer, AM | 1 |
| Daalhuisen, J | 1 |
| de Vos, AF | 1 |
| Bruno, MJ | 1 |
| van der Poll, T | 1 |
| Montanaro, MA | 1 |
| Lombardo, YB | 1 |
| González, MS | 1 |
| Bernasconi, AM | 1 |
| Chicco, A | 1 |
| Rimoldi, OJ | 1 |
| Basabe, JC | 1 |
| Brenner, RR | 1 |
| Caldefie-Chézet, F | 1 |
| Poulin, A | 1 |
| Enreille-Leger, A | 1 |
| Vasson, MP | 1 |
| Hisada, S | 1 |
| Shimizu, K | 2 |
| Shiratori, K | 2 |
| Kobayashi, M | 2 |
| Misugi, T | 1 |
| Ozaki, K | 1 |
| El Beltagy, K | 1 |
| Tokuyama, O | 1 |
| Honda, K | 1 |
| Ishiko, O | 1 |
| Meechan, AJ | 1 |
| Henderson, C | 1 |
| Bates, CD | 1 |
| Grant, MH | 1 |
| Tettey, JN | 1 |
| Ong, MM | 1 |
| Latchoumycandane, C | 1 |
| Boelsterli, UA | 2 |
| Díaz-Delfín, J | 1 |
| Morales, M | 1 |
| Caelles, C | 1 |
| Anzawa, R | 1 |
| Seki, S | 1 |
| Horikoshi, K | 1 |
| Taniguchi, M | 1 |
| Mochizuki, S | 1 |
| Jaeschke, H | 1 |
| Doi, S | 1 |
| Masaki, T | 1 |
| Arakawa, T | 1 |
| Takahashi, S | 1 |
| Kawai, T | 1 |
| Nakashima, A | 1 |
| Naito, T | 1 |
| Kohno, N | 1 |
| Yorioka, N | 1 |
| Phan, SH | 1 |
| Hu, B | 1 |
| Gangireddy, SR | 1 |
| Hogaboam, CM | 1 |
| Thannickal, VJ | 1 |
| O'Rourke, CM | 1 |
| Davis, JA | 1 |
| Saltiel, AR | 1 |
| Cornicelli, JA | 1 |
| Zhang, B | 1 |
| Saku, K | 1 |
| Arakawa, K | 1 |
| Horikoshi, H | 3 |
| Fujiwara, T | 2 |
| Shiomi, M | 1 |
| Ito, T | 1 |
| Tsukada, T | 1 |
| Tsujita, Y | 1 |
| Sigrist, S | 1 |
| Bedoucha, M | 1 |
| Chao, L | 1 |
| Marcus-Samuels, B | 1 |
| Mason, MM | 1 |
| Moitra, J | 1 |
| Vinson, C | 1 |
| Arioglu, E | 1 |
| Gavrilova, O | 1 |
| Reitman, ML | 1 |
| Jia, DM | 1 |
| Tabaru, A | 1 |
| Akiyama, T | 1 |
| Abe, S | 1 |
| Otsuki, M | 1 |
| McCarthy, KJ | 1 |
| Routh, RE | 1 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 1 |
| Oberkofler, H | 1 |
| Neschen, S | 1 |
| Esterbauer, H | 1 |
| Waldhäusl, W | 1 |
| Patsch, W | 1 |
| Fürnsinn, C | 1 |
| Yao, L | 1 |
| Mizushige, K | 1 |
| Noma, T | 1 |
| Murakami, K | 1 |
| Ohmori, K | 1 |
| Matsuo, H | 1 |
| Nicholas, SB | 1 |
| Kawano, Y | 1 |
| Wakino, S | 1 |
| Collins, AR | 1 |
| Hsueh, WA | 1 |
| Ma, LJ | 1 |
| Marcantoni, C | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Fogo, AB | 1 |
| Chvojková, S | 1 |
| Kazdová, L | 1 |
| Divisová, J | 1 |
| Hayashi, N | 1 |
| Asakawa, M | 1 |
| Takano, H | 1 |
| Nagai, T | 1 |
| Uozumi, H | 1 |
| Hasegawa, H | 1 |
| Kubota, N | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Komuro, I | 1 |
| Furuta, M | 1 |
| Yano, Y | 1 |
| Gabazza, EC | 1 |
| Araki-Sasaki, R | 1 |
| Katsuki, A | 1 |
| Hori, Y | 1 |
| Nakatani, K | 1 |
| Sumida, Y | 1 |
| Adachi, Y | 1 |
| Li, J | 1 |
| Kaneko, T | 1 |
| Wang, Y | 1 |
| Qin, LQ | 1 |
| Wang, PY | 1 |
| Sato, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
2 reviews available for troglitazone and Disease Models, Animal
| Article | Year |
|---|---|
[Troglitazone: its pharmacology and mechanism of action].
Topics: Animals; Chromans; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Humans; Hypoglyc | 1997 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
48 other studies available for troglitazone and Disease Models, Animal
| Article | Year |
|---|---|
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; | 1994 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy.
Topics: Animals; Disease Models, Animal; Endothelin-1; Female; Fetal Growth Retardation; Hypoxia; Immunohist | 2020 |
In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell L | 2017 |
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA- | 2018 |
Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat.
Topics: Animals; Cardiolipins; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Glutathione; Hep | 2018 |
Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism.
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Female; Hypoglycemic Agents | 2019 |
Role of insulin resistance in the pathogenesis and development of type 2 diabetes in WBN/Kob-Lepr(fa) rats.
Topics: Age Factors; Animals; Area Under Curve; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2013 |
Small-Molecule targeting of translation initiation for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chroma | 2013 |
In Vivo Detection of Mitochondrial Dysfunction Induced by Clinical Drugs and Disease-Associated Genes Using a Novel Dye ZMJ214 in Zebrafish.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Benzophenones; Carbocyanines; Chromans; Disease Mod | 2016 |
Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}.
Topics: Actins; Anilides; Animals; Antineoplastic Agents; Cell Adhesion; Chemotaxis; Chromans; Disease Model | 2008 |
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
Topics: Animals; Biomarkers, Tumor; Body Weight; Carcinogens; Chromans; Disease Models, Animal; Disease Susc | 2009 |
Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.
Topics: Alanine Transaminase; Animals; Butyrates; Cell Line; Cell Proliferation; Chromans; Disease Models, A | 2013 |
Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis; Colon; Dextran Sulfate; Disease Models, Animal | 2012 |
Pretreatment with troglitazone decreases lethality during endotoxemia in mice.
Topics: Administration, Oral; Animals; Chromans; Diet; Disease Models, Animal; Drug Interactions; Endotoxemi | 2002 |
Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipose Tissue; Animals; Cell Fractionation; Chromans; Diabetes Mellitus; Disease Models, Animal; Hy | 2002 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Mode | 2002 |
Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Chromans; Disease Models, Animal; Gene Expression Reg | 2003 |
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Topics: Actins; Animals; Cell Differentiation; Ceruletide; Chromans; Chronic Disease; Collagen; Disease Mode | 2005 |
Effect of troglitazone on the desaturases in a rat model of insulin-resistance induced by a sucrose-rich diet.
Topics: Animals; Chromans; Dietary Carbohydrates; Disease Models, Animal; Fatty Acid Desaturases; Insulin Re | 2005 |
Troglitazone reduces leptinemia during experimental dexamethasone-induced stress.
Topics: Adipocytes; Adipose Tissue; Animals; Anorexia; Blood Glucose; Body Weight; Chemical and Drug Induced | 2005 |
Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation.
Topics: Actins; Animals; Antineoplastic Agents; Chromans; Chronic Disease; Collagen Type I; Collagen Type II | 2005 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; | 2006 |
Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats.
Topics: Animals; Cells, Cultured; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; | 2006 |
Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.
Topics: Aconitate Hydratase; Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Anim | 2007 |
Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Topics: Adipocytes; Adipose Tissue; Animals; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Disease M | 2007 |
Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Diabetic Ketoacid | 2007 |
Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Animal; Humans; Hypoglyce | 2007 |
Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Apoptosis; Blotting, Western; Caspase 3; Chromans; Creatinine; Disease | 2007 |
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Differentiation; Cell Division; Cells, Culture | 2008 |
Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucose; Glucose Clamp | 1997 |
Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
Topics: Animals; Blood Glucose; Chromans; Disease Models, Animal; Fasting; Female; Glucose Tolerance Test; H | 1997 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vess | 1999 |
Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Down-Regulation; Gene Expressi | 2000 |
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, A | 2000 |
Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats.
Topics: Animals; Antioxidants; Body Weight; Carbon Dioxide; Carrier Proteins; Chromans; Diabetes Mellitus, T | 2000 |
Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment.
Topics: Animals; Blood Pressure; Chromans; Diastole; Disease Models, Animal; Echocardiography, Doppler; Hear | 2001 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabet | 2001 |
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Topics: Animals; Antihypertensive Agents; Base Sequence; Chromans; Disease Models, Animal; DNA Primers; Glom | 2001 |
PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis, Ulcerative; Crohn Disease; Disease Models, Ani | 2001 |
A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Disease Models, Animal; Fatty Acids; | 2001 |
Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis.
Topics: Amylases; Animals; Antineoplastic Agents; Blood Glucose; Chromans; Chronic Disease; Disease Models, | 2002 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce | 2002 |
Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Topics: Adipose Tissue; Animals; Blood Glucose; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 2002 |
Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats.
Topics: Acetaminophen; Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; Carbon Tetrachloride; C | 2002 |